Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2014-06-06
The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of
clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic
hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is
superior to placebo in the prevention of clinically-significant CMV infection through Week 24
post-transplant.
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Active, not recruiting
Merck Sharp & Dohme Corp.
Phase 3
2018-05-03
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus
valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The
primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is
demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks
post-transplant.
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Recruiting
Merck Sharp & Dohme Corp.
Phase 2
2019-01-11
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.
Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Recruiting
Amy C. Sherman, MD
Phase 2
2019-01-11
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
